Journal of Pharmaceutical Innovation

, Volume 7, Issue 1, pp 38–45 | Cite as

PAT within the QbD Framework: Real-Time End Point Detection for Powder Blends in a Compliant Environment

  • Geir Rune FlåtenEmail author
  • Ana Patricia Ferreira
  • Luke Bellamy
  • Paul FrakeEmail author
Research Article



A process analytical technology (PAT) method using a near infrared (NIR) spectrometer attached to a drum blender was developed for real-time end-point detection for an extragranular blend.

Methods and theory

The method and corresponding documentation are part of the control strategy for a recently filed and approved pharmaceutical product, and the method is currently in place and in use for manufacturing of this pharmaceutical product at GlaxoSmithKline.

Results and discussion

The immediate benefits are a dramatic reduction in blend time as well as real-time verification of blend homogeneity for every batch. The development of the blending end-point method is presented and a set of fundamental requirements for developing any PAT method is proposed.


It is discussed how the reported PAT end-point method fits with the proposed PAT framework, and the validation aspects required to achieve a compliant method for use in drug product manufacturing are presented.


QbD PAT Blend Chemometrics NIR Compliant 



This paper was presented at IFPAC10. Colleagues from the validation and automation departments in GSK are acknowledged for their support.


  1. 1.
    US Department of Health and Human Services. Food and Drug Administration, Guidance: PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance, 2004.Google Scholar
  2. 2.
    Flåten GR, Belchamber R, Collins M, Walmsley AD. Caterpillar—an adaptive algorithm for detecting process changes from acoustic emission signals. Anal Chim Acta. 2005;544:280–91.CrossRefGoogle Scholar
  3. 3.
    Sanchez FC, Toft J, van den Bogaert B, Massart DL, Dive SS, Hailey P. Monitoring powder blending by NIR spectroscopy. J Anal Chem. 1995;352:771–8.Google Scholar
  4. 4.
    Sekulic SS, Ward HW, Brannegan DR, Stanley ED, Evans CL, Sciavolino ST, et al. On-line monitoring of powder blend homogeneity by near-infrared spectroscopy. Anal Chem. 1996;68:509–13.PubMedCrossRefGoogle Scholar
  5. 5.
    De Maesschalck R, Sanchez FC, Massart DL, Doherty P, Hailey P. On-line monitoring of powder blending with near-infrared spectroscopy. Appl Spectrosc. 1998;52:725–31.CrossRefGoogle Scholar
  6. 6.
    Berntsson O, Danielsson L-G, Johansson MO, Folestad S. Quantitative in-line monitoring of powder blending by near infrared reflection spectroscopy. Powder Technol. 2002;185:185–93.CrossRefGoogle Scholar
  7. 7.
    Blanco M, Gozález Bañó R, Bertran E. Monitoring powder blending in pharmaceutical processes by use of near infrared spectroscopy. Talanta. 2002;56:203–12.PubMedCrossRefGoogle Scholar
  8. 8.
    Wargo DJ, Drennen JK. Near-infrared spectroscopic characterization of pharmaceutical powder blends. J Pharm Biomed Anal. 1996;14:1415–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Bellamy LJ, Nordon A, Littlejohn D. Real-time monitoring of powder mixing in a convective blender using non-invasive reflectance NIR spectrometry. Analyst. 2008;133:58–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Sulub Y, Wabuyele B, Gargiulo P, Pazdan J, Cheney J, Berry J, et al. Real-time on-line blend uniformity monitoring using near-infrared reflectance spectrometry: A non-invasive off-line calibration approach. J Pharm Biomed Anal. 2009;49:48–54.PubMedCrossRefGoogle Scholar
  11. 11.
    Skibsted ETS, Boelens HFM, Westerhuis JA, Witte DT, Smilde AK. Simple assessment of homogeneity in pharmaceutical mixing processes using a near-infrared reflectance probe and control charts. J Pharm Biomed Anal. 2006;41:26–35.PubMedCrossRefGoogle Scholar
  12. 12.
    Puchert T, Holzhauer CV, Menezes JC, Lochman D, Reich G. A new PAT/QbD approach for the determination of blend homogeneity: combination of on-line NIRS analysis with PC Scores Distance Analysis (PC-SDA). Eur J Pharm Biopharm. 2011;78:173–82.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.GlaxoSmithKlineTechnical, Ware GMSHertfordshireUK

Personalised recommendations